Two-dimensional (2D) perovskites are increasingly recognized as promising candidate materials for the next generation of ...

Emerging evidence suggests that gut biotics may help reduce inflammation and improve psoriasis severity, but larger studies ...

The mid-stage disappointment in Alzheimer’s disease delivers another blow to Neuphoria Therapeutics, which in November last year was forced to launch a strategic business review after a Phase 3 trial ...

Artelo Biosciences presents positive new data from a preclinical study in neuropathic pain from spinal cord injury at ICRS 2026 annual symposium: Solana Beach, California Friday, ...

Aurenar’s V-Link system uses transauricular vagus nerve stimulation to modulate brain inflammation in patients that have ...

A study reported June 30 in the journal Pain found that melatonin reduced pain by a “similar magnitude to widely used pain medications,” such as nonsteroidal anti-inflammatory drugs (NSAIDs) and ...

Researchers tested plant-derived prebiotic candidates against selected skin-associated bacteria and found that garlic, ...

United Therapeutics acquired privately-held biotechnology company Thymmune Therapeutics for $140 million in cash. The deal could include potential earn-out payments to former Thymmune equityholders of ...

Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with ...

Researchers have developed a predictive framework for 2D perovskite design to enable more efficient, stable solar cells.

Jul 2, 2026--United Therapeutics Corporation (Nasdaq: UTHR ) announced today it has acquired Thymmune Therapeut ...

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic ...